DNAI Insider Trading Activity and SEC Form 4 Filings
DNAI insider trading summary
No open-market insider purchases or sales of ProNAi Therapeutics Inc (DNAI) have been reported on SEC Form 4 in the past 12 months.
Latest DNAI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 22, 2016 | Wendy Chapman | SVP Clinical Operations | Sell | $21K (3,000 @ $7.01) |
| Feb 22, 2016 | Wendy Chapman | SVP Clinical Operations | Sell | $21K (3,000 @ $7.06) |
| Jan 22, 2016 | Wendi Rodigueza | Chief Scientific Officer | Sell | $10K (1,000 @ $9.66) |
| Jan 22, 2016 | Wendy Chapman | SVP Clinical Operations | Sell | $47K (5,000 @ $9.39) |
| Jan 21, 2016 | Wendi Rodigueza | Chief Scientific Officer | Sell | $10K (1,000 @ $10.32) |
| Jan 20, 2016 | Wendi Rodigueza | Chief Scientific Officer | Sell | $10K (1,000 @ $9.59) |
| Jan 15, 2016 | Nicholas Glover | CEO and President | Sell | $50K (5,000 @ $10.04) |
| Jan 12, 2016 | Chandra D Lovejoy | SVP of Reg. Affairs & Quality | Sell | $66K (5,562 @ $11.93) |
| Jan 12, 2016 | Chandra D Lovejoy | SVP of Reg. Affairs & Quality | Sell | $170K (15,411 @ $11.06) |
| Jul 21, 2015 | Samuel D Isaly | Director | Buy | $3.0M (175,000 @ $17.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.